Porres J C, Mora I, Gutiez J, Bartolome J, Quiroga J A, Bas C, Compernolle C, Ordi J, Chocarro A, Carreño V
Gastroenterology Department, Fundación Jiménez Diaz, Madrid, Spain.
Hepatogastroenterology. 1988 Feb;35(1):5-9.
A pilot study has been designed in order to determine the tolerance and effectiveness of recombinant interferon gamma (rIFN-gamma) in chronic hepatitis B virus (HBV) infection. Eight HBsAg, HBeAg, HBV-DNAp and HBV-DNA-positive patients were randomly assigned to one of two groups. In group 1, 0.25 mg of rIFN-gamma/m2 body surface was administered daily for 28 days to 4 patients. In group 2, 0.10 mg of rIFN-gamma was administered to 4 patients under the same conditions. All the patients concluded the treatment and were observed over 11 more months. During treatment, 6 out of 8 patients showed decreased levels of HBV-DNA and HBV-DNAp. In addition, by the 8th month of follow-up, six patients became negative for HBV-DNAp and 2 for HBcAg; all patients remained positive for HBV-DNA. At the end of the study, only 2 patients remained negative for HBV-DNAp, 4 for HBcAg and one became negative for HBV-DNA. No differences in antiviral effect were observed between the two groups. Furthermore, the T4/T8 lymphocytes ratio increased during therapy. In conclusion, rIFN-gamma may play a role in the treatment of chronic HBV infection.
为了确定重组干扰素γ（rIFN-γ）在慢性乙型肝炎病毒（HBV）感染中的耐受性和有效性，设计了一项初步研究。8例HBsAg、HBeAg、HBV-DNAp和HBV-DNA阳性患者被随机分为两组。在第1组中，4例患者每天给予0.25mg rIFN-γ/m²体表面积，持续28天。在第2组中，4例患者在相同条件下给予0.10mg rIFN-γ。所有患者均完成治疗，并在接下来的11个多月里接受观察。治疗期间，8例患者中有6例HBV-DNA和HBV-DNAp水平下降。此外，到随访第8个月时，6例患者HBV-DNAp转阴，2例HBcAg转阴；所有患者HBV-DNA仍为阳性。研究结束时，仅2例患者HBV-DNAp转阴，4例HBcAg转阴，1例HBV-DNA转阴。两组之间未观察到抗病毒效果的差异。此外，治疗期间T4/T8淋巴细胞比值升高。总之，rIFN-γ可能在慢性HBV感染的治疗中发挥作用。
